80 related articles for article (PubMed ID: 21786622)
21. [COMPARATIVE IMMUNOGENICITY STUDIES OF ADJUVANTS FROM VARIOUS SOURCES AND WITH DIFFERENT MECHANISMS OF ACTION FOR INACTIVATED INFLUENZA VACCINES].
Chernikova MI; Kashirina OS; Vasiliev YM
Zh Mikrobiol Epidemiol Immunobiol; 2015; (6):63-71. PubMed ID: 26950991
[TBL] [Abstract][Full Text] [Related]
22. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
[TBL] [Abstract][Full Text] [Related]
23. A clinical trial to assess the immunogenicity and safety of Inactivated Influenza Vaccine (Whole Virion) IP (Pandemic Influenza (H1N1) 2009 Monovalent Vaccine; VaxiFlu-S™) in healthy Indian adult population.
Kubavat AH; Mittal R; Patel PM; Jarsaniya DH; Pawar PR;
J Postgrad Med; 2011; 57(2):102-8. PubMed ID: 21654130
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N
Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
[TBL] [Abstract][Full Text] [Related]
26. Dose sparing with intradermal injection of influenza vaccine.
Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
[TBL] [Abstract][Full Text] [Related]
27. A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial.
Wu J; Li W; Wang HQ; Chen JT; Lv M; Zhou JC; Liang XF; Fang HH; Liu Y; Liu LY; Wang X; Zhang WL; Zhang XM; Song LF; Qiu YZ; Li CG; Wang JZ; Wang Y; Yin WD
J Infect Dis; 2010 Sep; 202(5):675-80. PubMed ID: 20632888
[TBL] [Abstract][Full Text] [Related]
28. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
[TBL] [Abstract][Full Text] [Related]
29. Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.
Le Corre N; Thibault F; Pouteil Noble C; Meiffrédy V; Daoud S; Cahen R; Charreau I; Bottigioli D; Dollinger C; Aboulker JP; Autran B; Morelon E; Barrou B
Vaccine; 2012 Dec; 30(52):7522-8. PubMed ID: 23103195
[TBL] [Abstract][Full Text] [Related]
30. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic.
Engelhard D; Zakay-Rones Z; Shapira MY; Resnick I; Averbuch D; Grisariu S; Dray L; Djian E; Strauss-Liviatan N; Grotto I; Wolf DG; Or R
Vaccine; 2011 Feb; 29(9):1777-82. PubMed ID: 21216315
[TBL] [Abstract][Full Text] [Related]
31. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
[TBL] [Abstract][Full Text] [Related]
32. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
[TBL] [Abstract][Full Text] [Related]
33. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
Reisinger KS; Block SL; Izu A; Groth N; Holmes SJ
J Infect Dis; 2009 Sep; 200(6):849-57. PubMed ID: 19673652
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and safety of pandemic H1N1 2009 vaccine among adults in field use, India.
Tandale BV; Pawar SD; Mishra AC
Vaccine; 2012 Mar; 30(12):2043-4. PubMed ID: 22001279
[No Abstract] [Full Text] [Related]
35. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients.
Bickel M; von Hentig N; Wieters I; Khaykin P; Nisius G; Haberl A; Stephan C; Herrmann E; Doerr HW; Brodt HR; Allwinn R
Clin Infect Dis; 2011 Jan; 52(1):122-7. PubMed ID: 21148530
[TBL] [Abstract][Full Text] [Related]
36. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
Hakim H; Allison KJ; Van De Velde LA; Li Y; Flynn PM; McCullers JA
Vaccine; 2012 Jan; 30(5):879-85. PubMed ID: 22155630
[TBL] [Abstract][Full Text] [Related]
38. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
Zuccotti G; Amendola A; Viganò A; Pariani E; Zappa A; Pogliani L; Giacomet V; Savarino A; Podestà A; Rottoli A; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2007 Sep; 25(37-38):6692-8. PubMed ID: 17697730
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
[TBL] [Abstract][Full Text] [Related]
40. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]